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Abstract
A small proportion of chronic myeloid leukemia patients treated with interferon-a (IFN-a) monotherapy are able to
discontinue the treatment without disease relapse although residual leukemia cells are present. Recently, we showed that
these patients have increased amount of NK-cells and a distinct blood cytokine profile. We now aimed to study the function
of NK- and T-cells in order to understand the role of the immune system in maintaining the treatment response after IFN-a
discontinuation. The study included 13 patients: 5 patients were still treated with IFN-a monotherapy (IFN-ON, median
treatment time 163 months) and 8 had stopped the treatment successfully (IFN-OFF, median time without therapy 42
months). Detailed immunophenotype and cytokine production of NK- and T-cells was analyzed with flow cytometry. In
addition, the cytotoxicity of NK-cells was studied using K562 as target cells and both the degranulation and direct killing
was measured. Compared to healthy controls, IFN-OFF patients had increased proportion of CD4+ effector memory
(CCR72CD45RA2; median 23% vs. healthy 16%, p = 0.009) and CD8+ central memory T-cells (CCR7+CD45RA2; median 26%
vs. healthy 14%, p = 0.004). Further, upon stimulation the IFN-c/TNF-a cytokine secretion by CD4+ T-cells was significantly
enhanced in IFN-OFF patients (median 13.7% vs. healthy 7.8%, p = 0.01), and CD4+ effector and central memory cells were
the main cytokine producers. No similar increase was observed in IFN-ON group (6.5%). In addition, the proportion of NK-
cells was significantly increased in IFN-OFF patients (median IFN-OFF 24%, healthy 13%, p = 0.04), but their direct killing of
K562 cells was impaired. The cytotoxicity of NK-cells was also diminished in IFN-ON patients. To conclude, in addition to
elevated NK-cell count, IFN-OFF patients have increased amount of memory T-cells, which are able to induce strong
cytokine response upon stimulation. This activity may contribute to the maintenance of prolonged remission after
successful IFN-a discontinuation.
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Introduction
Chronic myeloid leukemia (CML) is a relatively rare myelo-
proliferative disorder with an annual incidence of 1–2 cases per
100 000 individuals [1]. It is most often diagnosed in elderly
patients with the median age of 65 years. The pathogenesis of the
disease is well known and the leukemic transformation is caused by
a translocation (9;22) in hematopoietic stem cells (HSCs). This
results in a constantly active tyrosine kinase BCR-ABL, which in
turn causes unregulated proliferation of hematopoietic cells [2].
Tyrosine kinase inhibitors (TKIs; imatinib, dasatinib, nilotinib)
are the current first-line treatment in CML and they have
improved the prognosis significantly [3–5]. Before the TKI era,
CML patients were treated with interferon-a (IFN-a) [6], but only
a small proportion of patients responded well to the treatment.
However, surprisingly up to half of the patients who had achieved
complete cytogenetic remission (CCyR) were able to discontinue
the treatment without disease relapse [7,8]. Despite the increasing
understanding of the beneficial effects of IFN-a treatment, it is still
unclear why some CML patients are able to stop IFN-a treatment
and stay in remission without treatment. It is worth noticing that
these patients still have residual leukemic cells left but for unknown
reason they do not expand [9,10]. Therefore, it is conceivable that
IFN-a therapy has induced changes in the immune system, which
have a protective role. Supporting this theory, several studies have
reported that IFN-a induces specific immune response against
CML cells [11–14]. Due to these encouraging results, several
recent clinical trials aiming in the cure of CML have combined
IFN-a with TKI therapy [15,16]. Markedly, the combination
therapy has induced more rapid and deeper treatment responses
than TKI therapy alone [17]. Furthermore, adding IFN-a to
imatinib-treatment seems to increase the possibility to discontinue
the treatment successfully [18,19].
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Because of the comeback of IFN-a in the treatment of CML, it
is even more important to understand the immunomodulatory
mechanisms induced by the drug. Our group has previously shown
that IFN-a treated CML patients who have successfully discon-
tinued the treatment have increased amounts of NK-cells and
CD8+ T-cells, and a distinct cytokine profile [20]. To better
understand the role of NK- and T-cells in the putative curative
action of IFN-a, we now aimed to study their function and
phenotype in more detail, and analyzed primary samples from
CML patients who have successfully discontinued IFN-a mono-
therapy without disease relapse.
Patients and Methods
Study Patients and Samples
The study population included 13 chronic phase CML patients
treated with IFN-a monotherapy (Table 1) and no TKI treatment
has been used in these patients. 5 patients were currently treated
with IFN-a monotherapy (IFN-ON) and 8 had stopped the
treatment successfully (IFN-OFF). Two of the IFN-ON patients
were pregnant at the time of sample withdrawal and they are
marked with separate dots in the graphs. Samples from 14 age and
sex matched healthy volunteers were used as controls. The mean
age of the healthy controls was 55 years, and in the patient cohort
it was 56 years at the time of sample collection. The patient
number was limited in this study as TKIs are the current first-line
treatment in CML, and thus IFN-a monotherapy treated patients
are very rare. We therefore extended the patient sample collection
to 3 different countries (Finland, Czech Republic and Portugal).
The abbreviation IFN-ON is used for patients who were treated
with IFN-a at the time of sampling and IFN-OFF for patients who
have been able to stop the IFN-a treatment and have no ongoing
treatment for CML.
Peripheral blood (PB) samples were collected from all patients
and healthy controls. Mononuclear cells (MNCs) were separated
by Ficoll gradient centrifugation (GE healthcare, Buckingham-
shire, UK) and stored at liquid nitrogen or analyzed fresh.
Ethics Statement
All patients and healthy controls gave their written informed
consent and the study was approved by Helsinki University
Central Hospital (Helsinki, Finland), University Hospital Olomouc
(Olomouc, Czech Republic) and S. Joao University Hospital
(Porto, Portugal) ethics committees. The study was conducted in
accordance with the Declaration of Helsinki.
T-cell Phenotyping
Thawed MNCs were stained with anti-CD45-APC-H7 (clone
2D1), -CD3-PeCy7 (SK7), -CD4-PerCP (SK3), -CD45RA-Alexa-
Fluor700 (GB11) and -CCR7-PE (150503) (R&D Systems,
Minneapolis, MN, USA) antibodies. The stained MNCs were
acquired with FACSAriaII and analysed with FlowJo (Version
9.6.1, TreeStar). All antibodies were purchased from BD
Biosciences unless mentioned otherwise.
Activation of T-cells
Thawed MNCs were stimulated with anti-CD3 (clone OKT3,
2,5 mg/ml) and co-stimulatory anti-CD28 (L293, 1 mg/ml) and
anti-CD49d (L25, 0.5 mg/ml) (BD biosciences) and incubated for 6
hours at +37uC. MNCs without stimulation were used as controls.
GolgiStop (BD biosciences) was added to each well. After the
incubation, the cells were stained with the following antibodies:
CD45-APC-H7 (2D1), CD3-APC (SK7), CD4-PerCP (SK3),
CD8PE-Cy7 (SK1) and TCRcd-PE (11F2). After, the cells were
permeabilized and fixed according to the Cytofix Cytoperm (BD
biosciences, San Diego, CA, USA) kit’s protocol. Intracellular
staining was done with Granzyme B-Alexa Fluor 700 (GB11),
IFN-c-FITC (B27) and TNF-a-FITC (MAb11), and 50 000
CD45+ cells were analyzed with FACSAria. When the cytokine
secretion of CD4+ T-cell subsets was analyzed, TCRcd antibody
was replaced with CCR7-PE antibody, and CD45RA-Alexa-
Fluor700 was added to the panel.
T-cell Degranulation Assay
Thawed MNCs were stimulated with anti-CD3 (clone OKT3,
2,5 mg/ml) and co-stimulatory anti-CD28 (L293, 1 mg/ml) and
anti-CD49d (L25, 0.5 mg/ml) (BD biosciences) and incubated for 6
hours at +37uC. The cells were incubated for 6 hours in the
presence of antibodies for the degranulation marker CD107a-
FITC (H4A3) and CD107b-FITC (H4B4). MNCs without
stimulation were used as controls. After the incubation, the cells
were stained with the following antibodies: CD45-APC-H7 (2D1),
CD3-APC (SK7), CD4-PerCP (SK3), CD8PE-Cy7 (SK1), CCR7-
PE (11F2), CD45RA-AlexaFluor700 (GB11). 50 000 CD45+ cells
were analyzed with FACSAria.
Immunophenotyping of NK-cells
Freshly isolated MNCs were stained with CD45-APC-H7,
CD3-PE-Cy7, CD14-and CD19-Pacific Blue (clones Tu¨K4 and
SJ25-C1, Invitrogen), CD56-PE (NCAM16.2), CD16-PE-Tex-
asRed (3G8, Invitrogen), CD57-FITC (NK-1), CD62L-APC
(DREG-56), CD27-V500 (M-T271) and CD45RA-AlexaFluor700
(HI100). 50 000 CD45+ cells were acquired with FACSAria (BD
Biosciences, San Diego, CA, USA) and analyzed with FlowJo.
Cytotoxicity Assay
The target cell line K562 (Sigma-Aldrich, St. Louis, MO, USA)
was stained with CellTrace Violet Cell Proliferation (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s instructions
and rested over night at +37uC.
The next day, the proportion of NK-cells (CD3negCD16/56+)
from freshly isolated MNCs was measured by flow cytometry and
co-incubated with K562 cells in NK-cell:target ratios of 4:1 and
8:1 for 6 h at +37uC. All reactions were done in triplicates. After 6
hours, the cells were stained with Calcein-AM (stains only living
cells) from LIVE/DEADH Viability/Cytotoxicity Kit (Invitrogen)
according to the manufacturers instructions. Before cytometric
analysis, CountBright beads (Invitrogen) were added to each tube
and 5000 beads were gated and counted. The gate was set on
K562 cells (CellTrace positive) and the live K562 targets (Calcein-
AM positive) were calculated.
NK-cell Degranulation Assay
Freshly isolated MNCs were stimulated with K562 cells at ratio
10:1. MNCs without targets were used as negative controls. The
cells were incubated for 6 hours in the presence of antibodies for
the degranulation marker CD107a-FITC (H4A3) and CD107b-
FITC (H4B4). The cells were stained with CD45-APC-H7, CD3-
APC, CD16-PE-Cy7 (3G8) and CD56-PE. 50 000 CD45+ cells
were acquired with FACSAria and analyzed with FlowJo.
NK-cell Cytokine Assay
Fresh MNCs were stimulated with K562 in the ratio 10:1 or
with 2 nM PMA (Cell Signaling Technology, Beverly, MA, USA)
and 0.02 mg/ml of Calcium Ionophore (Sigma-Aldrich, Saint
Louis, MO, USA). GolgiStop (BD) was added to each well. After
6 h incubation at +37uC, the cells were stained with CD16-PE-
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Cy7, CD56-PE, CD45-APC-H7 and CD3-APC. The cells were
then permeabilized and fixed according to the Cytofix Cytoperm
kit’s protocol (BD). Intracellular cytokines IFN-c and TNF-a were
stained with anti-IFN-c- and anti-TNF-a-FITC and 50 000
CD45+ cells were acquired with FACSAria and analyzed with
FlowJo.
Statistical Analysis
All statistical analyses were performed with GraphPad Prism
(GraphPad Software Inc., CA, USA). Nonparametric Mann-
Whitney test was used for comparison between two groups and
two-way Anova for comparison in the cytotoxicity assay. P,0.05
was considered statistically significant.
Results
CML Patients Who have been Able to Stop IFN-a
Treatment have Increased Amount of Memory CD4+ and
CD8+ T-cells
To understand the nature and function of T-cells in IFN-a
treated CML patients, PB MNCs were phenotyped with memory
markers such as CCR7 and CD45RA. In IFN-OFF patients, the
proportion of central memory CD8+ cells (CCR7+CD45RA2) was
significantly increased when compared to healthy controls (median
IFN-OFF 25.7% vs. healthy 14.3% of CD8+ T-cells, p = 0.0037,
Figures 1A and 1D). No significant differences were observed in
the CD8+ effector memory cells (median IFN-OFF 39.9%, healthy
35.2%, p = 0.87, Figure 1E) or naı¨ve CD8+ T-cells
(CCR7+CD45RA+) (median IFN-OFF 20.7% vs. healthy 25.3%
of CD8+ T-cells, p = 0.95, Figures 1A and 1B). However, both
patient groups seemed to have a decreased proportion of CD8+
CD45RA+ effector memory T-cells (TEMRA) when compared to
the healthy (median IFN-OFF 10.3%, IFN-ON 7.9%, healthy
23.8%, p = 0.002, Figure 1C).
In contrast to the CD8+ T-cell compartment, the effector
memory (CCR72CD45RA2) T-cell pool was significantly en-
larged in IFN-OFF patients compared to healthy controls (median
IFN-OFF 22.6% vs. healthy 16.1% of CD4+ T-cells, p = 0.009,
Figures 2A and 2E). The IFN-OFF group also seemed to have an
increased proportion of CD4+ CD45RA+ effector memory T-cells
(TEMRA) when compared to the healthy (median IFN-OFF 6.1%,
healthy 3.6%, p = 0.07, Figure 2C). No differences were observed
in the central memory (CCR7+CD45RA2) subset (Figure 2D), but
IFN-OFF patients had a lower frequency of naı¨ve CD4+ T-cells
(median IFN-OFF 21.2% vs. healthy 42.5% of CD4+ T-cells,
p = 0.049, Figures 2A and 2B).
Table 1. Patient characteristics.




(months) Reason for STOP/no STOP Course of IFN-a therapy Response
IFN-ON 1 CP m 62 144 No severe side-effects,
PCR positive
auto-PBSCT, 1.5 MU/2x weekly – cont.
For 12 years
MR4.0
IFN-ON 2 CP f 35 240 No severe side effects, 2 MU/3x weekly – cont. for 20 years. CMR
doctor hesitates to stop,
sometimes PCR positive
IFN-ON 3 CP m 29 163 Patient does not want to stop 5.5 MU/6x weekly – cont. for 14 years. MR4.0
IFN-ON 4 CP f* 20 168 no severe side-effects busulfanc, 1.5 MU/2x weekly MMR
PCR positive – cont. for 12 years.
IFN-ON 5 CP f* 40 8 Diagnosed during pregnancy For 8 months CMR
IFN-OFF 1 CP m 44 204 Nephrosis, IFN-a (10 years and stopped), CMR
low hemoglobin (80) 7 years no therapy
IFN-OFF 2 CP m 53 170 Side-effects
(nausea, muscle pain),
IFN-a (11 years and stopped), CMR
good response,
patient requested
3 years no therapy
IFN-OFF 3 CP f 53 134 Good response auto-PBSCT, IFN-a (8 years and stopped), CMR
3 years no therapy
IFN-OFF 4 CP m 59 86 Good response IFN-a (5 years and stopped), CMR
2 years no therapy
IFN-OFF 5 CP m 42 84 Good response IFN-a (5 years and stopped), CMR
3 years no therapy
IFN-OFF 6 CP m 36 112 Good response auto-PBSCT, IFN-a (5 years and stopped), CMR
4 years no therapy
IFN-OFF 7 CP f 41 172 Good response auto-PBSCT, IFN-a (7 years and stopped), CMR
7 years no therapy
IFN-OFF 8 CP f 54 168 Good response IFN-a (10 years and stopped), 4 years no
therapy
CMR
* = Pregnant. Abbreviations: CP, chronic phase; m, male; f, female; dg, diagnosis; cont, continued; MU, million unit; MR4.0, molecular response 4.0, CMR, Complete
Molecular Response; MMR, Major Molecular Response; Auto-PBSCT, autologous peripheral blood stem cell transplantation.
doi:10.1371/journal.pone.0087794.t001
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In IFN-ON group, the division of different T-cell populations
(especially the proportion of naı¨ve CD4+ and CD8+ cells) varied
significantly between individual patients, which could be due to
the heterogeneous clinical situation (two patients were pregnant
and they are marked with separate dots in Figures 1 and 2).
Cytokine Secretion by CD4+ T-cells is Significantly
Increased in IFN-OFF Group
To study the activation and cytokine secretion potential of T-
cells, MNCs were stimulated with anti-CD3, anti-CD28 and anti-
CD49d, and the production of IFN-c and TNF-a was measured
by flow cytometry. CD4+ T-cells were more active to secrete
cytokines in IFN-OFF patients than in healthy controls and
significantly higher proportion of cells responded by TNF-a/IFN-
c secretion (IFN-OFF median 13.7%, IFN-ON 6.5%, healthy
7.8%, p = 0.01, Figures 3A and 3B). The cytokine secretion of
CD8+ T-cells was similar in IFN-a treated CML patients and in
healthy controls (IFN-OFF 9.5%, IFN-ON 4.8%, healthy 15.3%,
p = 0.3, Figure 3C).
In addition, we analyzed the cytokine secretion of distinct CD4+
and CD8+ T-cell memory subsets from 3 IFN-OFF patients. In the
CD4+ cells, effector memory and central memory CD4+ T-cells
Figure 1. CD8+ T-cells from IFN-OFF patients have an increased central memory compartment. Memory status of CD8+ T-cells was
determined by FACS-analysis using anti-CD45RA and –CCR7 antibodies. A) Examples of 3 IFN-OFF, 3 IFN-ON and 3 healthy controls. TCM, T central
memory cells; TEM, T effector memory cells; TEMRA, T CD45RA+ effector memory cells B) The proportion of naı¨ve CD8+ T-cells (CD45RA+CCR7+), C)
CD8+ CD45RA+ effector memory T-cells (CD45RA+CCR72), D) CD8+ central memory T-cells (CD45RA2CCR7+), and E) CD8+ effector memory T-cells
(CD45RA2CCR72) from all CD8+ T-cells. White dots represent pregnant patients in IFN-ON group (Table 1).
doi:10.1371/journal.pone.0087794.g001
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were clearly most active cell subsets in cytokine secretion (more
than 80% of all cytokines secreted by CD4+ cells came from
effector memory and central memory T-cells) (Figure 4A). In
CD8+ compartment both naı¨ve and memory cells secreted
cytokines, but interestingly the CD8+ effector cells responded
especially well to stimulation by secreting cytokines (Figure 4C).
Degranulation responses were also evaluated from 2 patients from
whom suitable samples were available, and the proportion of
CD107 expressing increased after the stimulation (Figure 4E).
However, due to low number of patients studied, no further
conclusions can be withdrawn. The proportion of potentially
cytotoxic Granzyme B+ T-cells was similar in IFN-OFF patients
and healthy controls (data not shown).
IFN-OFF Group has Increased Proportion of NK-cells
Displaying a Mature Phenotype
Similarly as shown previously [20], the proportion of NK-cells
from lymphocytes was significantly increased in IFN-OFF patients
(median IFN-OFF 24%, healthy 13%, p = 0.04, Figure 5A), while
there was no significant difference in the IFN-ON group (7%). In
the absolute NK-cell number the differences between the groups
did not reach statistical significance (IFN-OFF median 0.29?109
Figure 2. CD4+ T-cells from IFN-OFF patients have an increased effector memory compartment. Memory status of CD4+ T-cells was
determined by FACS-analysis using anti-CD45RA and –CCR7 antibodies. A) Examples of 3 IFN-OFF, 3 IFN-ON and 3 healthy controls. TCM, T central
memory cells; TEM, T effector memory cells; TEMRA, T CD45RA+ effector memory cells. B) The proportion of naı¨ve CD4+ T-cells (CD45RA+CCR7+), C)
CD45RA+ effector memory CD4+ T-cells (CD45+CCR72), D) CD4+ central memory T-cells (CD45RA2CCR7+), and E) CD4+ effector memory T-cells from
all CD8+ T-cells. White dots represent pregnant patients in IFN-ON group (Table 1).
doi:10.1371/journal.pone.0087794.g002
T-Cells in CML Patients Treated with IFN-a
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e87794
cells/L, healthy 0.18?109 cells/L, p = 0.3, Figure 5B). The majority
of NK-cells in IFN-OFF patients were CD56DIM cells (median
IFN-OFF 97%, healthy 95%, p = 0.16, Figures 5C and D). NK-
cells from IFN-ON patients included significantly less CD56DIM
cells than NK-cells from IFN-OFF or healthy controls (83.7%,
0.13?109 cells/L). Furthermore, the CD57 expression (marker for
mature phenotype) in CD56DIM NK-cells seemed to be higher in
IFN-OFF group (median IFN-OFF 72.8%, healthy 63.8%,
p = 0.27, Figure 5E) and lower in IFN-ON group (49%), while
the CD62L (adhesion molecule) expression was increased in IFN-
ON patients (Figure 5F). A trend towards lower CD27 expression
in NK-cells was also observed in IFN-OFF group (Figure 4G), but
no statistically significant differences existed. To conclude, the
majority of NK-cells in IFN-OFF patients had a mature
CD56DIMCD57+ phenotype lacking the expression of CD62L
and CD27.
NK-cells from IFN-OFF Patients have Decreased Cytotoxic
Capacity
To analyze the function of the increased number of NK-cells in
IFN-OFF patients, we first measured their cytotoxicity by using
MNCs as effector cells and NK-cell susceptible cell-line (K562) as
target cells (effector: target ratio was standardized based on NK-
cell percentage). Surprisingly, in the both of the patient groups the
killing was decreased (median IFN-OFF 1% at ratio 4:1, IFN-ON
1%) when compared to healthy controls (17%) (Figure 6). From
three patients (2 IFN-OFF and 1 IFN-ON) the NK-cell killing
assay was concomitantly done with purified NK-cells and MNCs
and the results were concordant confirming the impaired NK-cell
cytotoxicity.
The Degranulation of NK-cells from IFN Patients is Similar
as in Healthy Controls
To further determine the function of NK-cells in IFN-OFF
patients, the degranulation capability was measured by standard
CD107 degranulation assay. Interestingly, the CD56DIM NK-cells
from IFN-OFF patients seemed to degranulate without stimula-
tion, but there was no statistically significant difference when
compared to the healthy controls (CD107 expressing cells in IFN-
OFF group median 6.5% vs. 3.8% in healthy, p = 0.11, Figure 7A).
After the stimulation with K562 cells, the degranulation was
similar in IFN-OFF patients as in healthy controls (median IFN-
OFF 12.9%, healthy 17.5%, p = 0.28, Figure 7B). Similarly, the
cytokine production (TNF-a/IFN-c) after the K562 stimulation
Figure 3. CD4+ T-cells from IFN-OFF patients are more prone to secrete TNF-a/IFN-c than CD4+ T-cells from the healthy. T-cells were
stimulated with anti-CD3, –CD28 and -CD49d. After 6 h incubation, cell surface markers and intracellular cytokines were stained and analyzed with
flow cytometry. A) Non-stimulated and stimulated TNF-a/IFN-c secretion of CD3+ T-cells. Shown are 3 representative patients from each group (IFN-
OFF, IFN-ON and healthy). Percentages are calculated from CD4+ T-cell population. B) TNF-a/IFN-c secretion of CD4+ T-cells in all patients C) TNF-a/
IFN-c secretion of CD8+ T-cells in all patients. White dots represent pregnant patients in IFN-ON group (Table 1).
doi:10.1371/journal.pone.0087794.g003
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did not markedly differ between the groups, but overall, the NK-
cells from IFN-OFF patients were poor cytokine producers
(Figures 7C and 7D).
Discussion
The re-introduction of IFN-a to CML treatment has gained
significant interest lately. Several studies have shown that the
combination of IFN-a with imatinib results in better and faster
treatment responses [15,21] The addition of IFN-a to imatinib
Figure 4. Function of T-cell subsets in IFN-OFF patients. A) T-cells were stimulated with anti-CD3, –CD28 and -CD49d and after 6 h incubation,
cell surface markers and intracellular cytokines were stained and analyzed with flow cytometry. The cytokine secretion of CD4+ T-cell subsets (effector
and central memory, naı¨ve and temra cells) was analyzed separately. The percentage values present the proportion of cytokine secreting cells from all
CD4+ cells showing that the effector and central memory T-cells are the main cytokine producers. B) The proportion of cytokine secreting effector
and central memory CD4+ T-cells were also analyzed separately and the % values show the proportion of positive cells from a subset in question. C)
Cytokine secretion of CD8+ T-cell subsets and D) the proportion of cytokine secreting effector and central memory CD8+ T-cells separately. E)
Degranulation of CD8+ T-cells was analyzed by CD107a/b expression with flow cytometry after 6 h incubation with anti-CD3, -CD28 and -CD49d.
Unstimulated MNCs were used as a control.
doi:10.1371/journal.pone.0087794.g004
T-Cells in CML Patients Treated with IFN-a
PLOS ONE | www.plosone.org 7 January 2014 | Volume 9 | Issue 1 | e87794
treatment has also been reported to increase the possibility to
discontinue treatment successfully. For example, Burchert et al.
has reported that 75% of CML patients receiving IFN-a/imatinib
combination therapy are able to stay in remission after discon-
tinuing imatinib treatment [19], whereas a lower frequency (30–
40%) of successful treatment discontinuations have been observed
after imatinib monotherapy [22,23]. IFN-a therapy has also been
shown to be effective in some TKI resistant patients such as in
difficult-to-treat T315I mutation positive patients [24,25]. Wheth-
er the beneficial results of IFN-a therapy are due to immunological
properties is under debate, but also our results support the view
that successful IFN-a therapy induces numerical and functional
changes in the immune effector cells, which may contribute to
excellent treatment responses.
In this project we focused to study the immune cell function and
phenotype. Our cohort consisted of IFN-a monotherapy treated
CML patients, which is a very rare group of patients due to
current use of TKIs as a standard first-line treatment. However, as
the treatment responses can be considered exceptional in these
patients (either state of the minimal residual disease with IFN-a
monotherapy or long-lasting remission after IFN discontinuation),
they may help us to understand the requirements for successful
treatment discontinuation. Interestingly, our results showed that
IFN-OFF patients had enlarged CD8+ central memory T-cell
Figure 5. NK-cells from IFN-OFF patients have a mature phenotype. NK-cell proportions and surface markers CD62L, CD57 and CD27 were
analyzed with flow cytometry and absolute NK-cell counts were counted from total lymphocyte numbers. A) The proportion of NK-cells in IFN-OFF
and IFN-ON patients B) Absolute amount of NK-cells in IFN-ON and IFN-OFF patients C) The proportion of CD56DIM NK-cells from CD56 NK-cells in
IFN-ON and IFN-OFF patients D) Absolute amounts of CD56DIM NK-cells in IFN-ON and IFN-OFF patients. E) CD57 expression in CD56DIM NK-cells. F)
CD62L expression in CD56DIM NK-cells G) CD27 expression in CD56DIM NK-cells. White dots represent pregnant patients in IFN-ON group (Table 1).
doi:10.1371/journal.pone.0087794.g005
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compartment. These cells are CCR7+CD45RA2 cells that have
encountered their cognate antigen, expanded, and they act mainly
as a reservoir in the lymph nodes for later effector functions against
the same antigen. Both the CD8+ central and effector memory T-
cells have been used in the adoptive cancer immunotherapy as
they have high lytic capacity and are able to produce IFN-c as also
observed in our study [26,27]. Especially antigen specific CD8+
central memory T-cells have shown to possess superior antitumor
immunity in vivo and eradicate even large melanoma tumors [28].
Although the antigen specificity of CD8+ central memory T-cells is
not known in our patients, the CD8+ central memory T-cell
compartment was markedly different in IFN-OFF patients when
compared to healthy controls, and it could be hypothesized that
these cells have a role in anti-tumor immunity. Together with a
low number of CD8+TEMRA cells (recently activated peripheral
effectors) observed in IFN-OFF group, the findings are in line with
the stable remission status of the IFN-OFF patients. Furthermore,
it is noteworthy that in the IFN-OFF group the median time
without treatment was close to 4 years suggesting that the
differences observed were no longer direct effects of IFN-a, but
long-term changes in the immune system. This is supported with
the data from the follow-up samples from some patients showing
that the immune-profile is unchanged at the later time-points.
In line with our results, Usuki et al has demonstrated in a small
cohort of CML patients (n = 9) that patients who were able to stay
in remission after imatinib discontinuation had increased amount
of CD45RO+ memory CD8+ cells when compared to healthy
volunteers or relapsing patients [29]. This needs to be confirmed
in larger patient cohorts, but it suggests that CML patients who
are able to maintain the remission after the therapy discontinu-
ation may share similar features in their immunoprofile despite of
the pre-existing therapy.
Figure 6. The cytotoxicity of NK-cells from IFN-OFF and IFN-ON
patients is impaired. MNCs were used as effector cells and K562 cells
as target cells. The NK-cell percentage was determined by flow
cytometry and the number of effector MNCs was counted accordingly.
Cells were co-incubated for 6 h at +37uC at effector:target ratios 4:1 and
8:1. The graphs present alive K562 cells after the co-incubation with
effector cells.
doi:10.1371/journal.pone.0087794.g006
Figure 7. Degranulation and cytokine secretion of NK-cells. MNCs were incubated for 6 hours with and without K562 cells at +37uC and the
degranulation (CD107a/b expression) and cytokine secretion of NK-cells was measured by flow cytometry. A) Degranulation of NK-cells without
stimulation B) Degranulation of NK-cells after the stimulation with K562-cells C) IFN-c/TNF-a secretion by NK-cells without stimulation D) IFN-c/TNF-
a secretion by NK-cells after the stimulation with K562-cells. White dots represent pregnant patients in IFN-ON group (Table 1).
doi:10.1371/journal.pone.0087794.g007
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In addition to changes in the CD8+ T-cell pool, IFN-OFF
patients had significantly increased amount of CD4+ effector
memory cells. CD4+ effector memory cells are able to respond
rapidly to antigen encounter by cytokine secretion [30]. In
accordance, our results showed that when MNCs from IFN-OFF
patients were stimulated, CD4+ cells responded significantly more
active by secreting Th1-type cytokines TNF-a/IFN-c than CD4+
T-cells from healthy controls, and effector and central memory
CD4+ cells were the main cytokine producers. The cytokine
production in turn can activate the generation of cytolytic CD8+
T-cells [31] or act directly against the cancer [32], and thus, CD4+
effector memory cells are crucial for the generation of antitumor
immune responses [33].
Similarly as shown in our previous report [20], we noticed that
IFN-OFF group had an expansion of mature CD56DIMCD62L-
LOWCD27LOWCD57+ NK-cells in the peripheral blood. Although
CD56DIM NK-cells have typically been suggested to act as
cytotoxic cells, to our surprise, the killing activity in response to
K562 cells was lower in IFN-OFF patients than in healthy
controls. This is somewhat in contrast to previous results, which
have shown that during IFN-a therapy, NK-cell cytotoxicity
against K562 cells and autologous CML cells is increased [34,35].
However, those results were obtained from patients who had just
started IFN-a therapy compared to our IFN-OFF group, which
has already been without treatment for several years. Constant
activation with IFN-a can also lead to changes in the NK-cell
phenotype [36], and the CD57 expression found in most of the
NK-cells in IFN-OFF group also implies to exhausted terminal
stage cells. This could explain why they did not react properly
against third party target cells (K562) in vitro. Supporting this
theory, it has been reported that CD56DIMCD62L2 NK-cells are
not as capable of proliferating as CD56DIMCD62L+ NK-cells [37].
In addition to direct cytolytic abilities, NK-cells may also have
other unknown functions in tumor immunology such as memory
properties. The participation of NK-cells in the adaptive immune
system is still under debate, but recent studies suggest that NK-
cells are able to live long [38] and produce memory-like responses
[39–41]. However, there is no specific immunophenotype known
for NK memory cells [42], and therefore we were not able to
analyze this aspect in our patient cohort.
Taken together, our results show that IFN-OFF patients have
significant numerical and functional changes in both the T- and
NK-cell compartments, which may contribute to the maintenance
of prolonged remission after successful IFN-a discontinuation.
Further studies in upcoming clinical trials evaluating the effect of
IFN-a+TKI combination are needed to confirm these preliminary
results.
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